The International Prognostic Scoring System-Revised (IPSS-R) is one standard for myelodysplastic syndrome (MDS) risk stratification. It divides patients into five categories including an intermediate subset (IPSS-R int-risk). Outcomes and clinical interventions for patients with IPSS-R int-risk are not well defined. We performed an analysis of outcomes of this group of patients. Out of 3167 patients, a total of 298 were identified with IPSS-R int-risk MDS and retrospectively analyzed to assess characteristics affecting outcomes. Cox proportional hazard models for overall survival (OS) were performed to identify statistically significant clinical factors that influence survival. Age of 66 years or greater, peripheral blood blasts of 2% or more, and history of red blood cell (RBC) transfusion were significantly associated with inferior survival. Based on these features, MDS patients with IPSS-R int-risk were classified into two prognostic risk groups for analysis, an int-favorable group and an int-adverse group, and had significantly divergent outcomes. Sequential prognostication was validated using two independent datasets comprising over 700 IPSS-R int-risk patients. The difference in median survival between int-favorable and int-adverse patients was 3.7 years in the test cohort, and 1.8 and 2.0 years in the two validation cohorts. These results confirm significantly variable outcomes of patients with IPSS-R int-risk and need for different prognostic systems.
Scoring System (IPSS-R) has become one of the gold standard models for risk stratification and prognostication for patients with MDS. 3, 4 It distinguishes patients based on key clinical characteristics and divides them into five well-defined risk groups: very low, low, intermediate, high, and very high. IPSS-R scores the disease based on marrow blast percentage, cytogenetics, hemoglobin levels, absolute neutrophil count (ANC), and platelet count.
In the original IPSS scoring system 5 patients were frequently considered in binary fashion, as either lower-risk or higher-risk MDS. For IPSS-R, very low-risk and low-risk patients may be considered for more conservative and lower risk strategies, whereas high-risk and very high-risk patients are often treated more assertively. The fifth group of IPSS-R classified patients, whose Kaplan-Meier survival bisects survival of lowrisk and high-risk groups, is the intermediate-risk (int-risk) category.
These patients present a more challenging clinical dilemma, due to risk uncertainty. While as a group they have an intermediary survival, it is possible that they actually have a more widely variable disease course and outcome. This degree of variance may lead to uncertainty in clinical management, and suggests the group may represent patients that are more challenging to classify, rather than simply those with a mid-range prognosis. [15] [16] [17] 3 a more refined risk classification system for this particular group is warranted. We retrospectively studied a large cohort of patients exclusively with IPSS-R int-risk MDS to identify whether particular characteristics indicated whether a patient had a more or less favorable prognosis. We assessed patient outcomes based on three identified influential factors, and our results indicate that prognosis of this subset of patients is variable with potential implications on their treatment and clinical trial design.
| METHODS

| Patients
A retrospective patient-centered analysis was conducted at the Uni- Availability of complete data was mandatory for patient selection.
Patients having therapy-related MDS disease or chronic myelomonocytic leukemia were excluded. After applying these inclusion criteria, the analytic cohort consisted 298 patients identified as IPSS-R int-risk.
All patients provided informed written consent.
| Covariates and outcome measures
The primary outcome was overall survival (OS), defined as the time from the date of diagnosis to the date of death due to any cause. The following characteristics were collected: demographic details such as age, sex and race; IPSS-R score (as well as IPSS score); laboratory investigations including hemoglobin level, serum ferritin level, white blood cell (WBC) count, platelet count, ANC, percentage of peripheral blood (PB) and bone marrow (BM) blasts at diagnosis; and the number of cytopenias defined as ANC <1.8 × 10 9 /L, hemoglobin <10 g/L, and platelet count <100x10. 6 Analysis was performed for the presence of known gene mutations, including FLT3-D835, FLT3-ITD, and in IDH1,   IDH2, JAK2, KIT, NPM1, TET2, TP53, NOTCH1, 
| Statistical methods
Summary statistics were used to describe the overall study population. Kaplan-Meier (KM) product limit method 11 CI's were calculated using R. Incidence rates were compared using a two-sided t test in R. Additional methods for analysis of transfusion data is described in Supporting Information. Bootstrap method was used for internal validation of the stratification score. 16 For each bootstrap data set, differences in median and 1-to 5-year survival rates were calculated between the two risk groups of patients (score 0-1 vs. score 2-4) using Kaplan-Meier estimation. 95% confidence intervals of these differences between the two subgroups were determined by 1000 bootstrap resamples. Statistical analysis was performed using Stata/SE version 14.1 statistical software (Stata Corp. LP, College Station, TX).
| External validation
The proposed scoring system was tested for validation using external 3 | RESULTS
| Patient characteristics
A total of 298 patients with int-risk MDS according to IPSS-R scoring were included in the analysis. Two-hundred and eighteen (73.2%) patients were older than 60 years. Most of the patients had an ECOG performance status score of 0 or 1 (n = 282; 95.6%). A total of 141 patients (47.4%) had been transfused with either RBC or platelets (n = 33; 11.1% had received both) at the time of diagnosis. Table 1 shows the demographic and baseline clinical characteristics of the patient cohort. The cytogenetic scoring (IPSS-R) was very good/good for the majority of patients (n = 225; 75.5%); intermediate for 57 (19.1%) , and poor/very poor for 16 (5.4%) patients. Mutation testing was limited for most leukemia-associated genes and is shown in Supporting Information (Table S1 ). The median follow-up time was 23.7 months (range: 0-189.4). Table 1 
| Univariate and multivariate survival analyses
Association between overall survival and patient characteristics was assessed by univariate and multivariate analysis (Supporting Information Table S2 ). In univariate analysis, significant statistical association was found between overall survival and the following covariates:
hemoglobin (P = .003), neutrophil percentage (P = .007), performance status (P = .047), red blood cell (RBC) transfusion dependency (P < .001), age (P < .001), peripheral blast percentage (P < .001), ferritin (P < .001), and β2-microglobulin levels (P < .001).
Ferritin levels ≥1222 ng/mL were associated with inferior survival (median survival = 22 months vs. 32 months for patients with ferritin <1222 ng/mL), however this was not included in the multivariate analysis since ferritin levels were unavailable for 61% of patients. Full mutation testing was not available for a majority of patients, and when mutations were investigated for patients stratified by OS, no significant correlations were discovered (data not shown). Due to incomplete data and few numbers of patients with most mutations, mutation status was not included in the univariate or multivariate analysis. Fitting results of the full and reduced multivariate Cox models are shown in Supporting Information Table S2 . Based on the reduced model, age ≥ 66 years (<.001), peripheral blood blast percentage ≥ 2% (P = .009) and RBC transfusion dependency (P = .003) were each independently and significantly associated with a less favorable survival.
| Sequential stratification based on age, PB blasts, and RBC transfusion
We proposed an optimal dichotomous stratification based on the findings from the reduced Cox proportional hazards multivariate model using the using the values assigned to each patient. The covariates included in the multivariate model were factors identified as significant by backward elimination method analysis as described. 15 The calculated risk value was defined by each coefficient multipliers to weight relative influence of dichotomized covariates on risk, and was The median risk value among all patients was 0.89 and was considered the cut-off for additional analysis. To further simplify patient assessment, each coefficient was divided by 0.51 (smallest coefficient in the reduced multivariate model) and rounded to the nearest integer, providing a simple 4-point system by which risk could be assessed. Table 2 shows the coefficients and hazard ratios with their weighted points.
| Divergent risk based on sequential stratification
Intermediate-risk MDS patients were stratified as determined by adding points from three individual clinical characteristics: patients with a score of 0-1 were considered favorable (int-favorable) and patients with a score of 2-4 were considered less favorable (int-adverse). There RBC transfusion rate was significantly lower in int-favorable patients than in int-adverse patients (IRR: 0.73; 95% CI 0.69-0.77; P < .0001, Figure 1D ). Int-favorable patients (n = 94), had a RBC transfusion rate of 7.54 units/patient-year (95% CI: 7.27-7.82), while int-adverse patients (n = 101) were transfused RBC at a rate of 10.27 units/patient-year (95% CI: 9.88-10.68). Platelet transfusion rate was also significantly lower in int-favorable patients compared to int-adverse (IRR: 0.81; 95% CI: 0.76-0.86; P < .0001, Figure 1D ).
Platelet transfusion rate was 7.61 units/patient-year (95% CI:
7.32-7.89 in the int-favorable group (n = 87) vs 9.38 units/patientyear (95% CI: 8.97-9.82) in the int-adverse risk group (n = 81).
We compared the survival outcomes between the sequentially stratified risk groups when these patients were classified according to IPSS (Figure 2A,C) ). Sequential stratification was significantly prognos- Figure S1 ).
The influence of age ≥66 years was strongest in our sequential stratification. Age-adjusted IPSS-R (IPSS-RA) 3 was considered in our test cohort, and this classification also sequentially stratified patients based on the additional consideration of age according to IPSS-RA (P < .001, see Supporting Information Figure S2A ). Finally, to assess the influence of PB blasts and RBC transfusion requirement regardless of age, the original reduced model was analyzed without age as a factor. The difference in overall survival remained strongly significant (P = 0.003, Supporting Information Figure S2B ), indicating these two factors are influential among int-risk patients independent of age.
| Treatment effects for int-favorable and intadverse patients
We assessed the association between the primary treatment received and OS among all patients, and those who were sequentially stratified.
Supporting Information Table S3 shows the univariate Cox proportional hazard models for initial treatment effect overall and by sequential stratification. There were no significant differences by treatment among the entire int-risk group, however there were trends for better overall survival among 13 patients who underwent transplant and 65 patients who received a hypomethylating agent (HMA) when compared with patients without treatment (P = .08 and.09, respectively). Univariate assessment was performed in both sequentially stratified risk groups (Continues) individually. In the int-favorable group, patients treated with a HMA had significantly improved survival compared to those without treatment (P = .05), however this was not true for int-adverse patients (P = .73). The use of transplant in the int-adverse was associated with greater risk of death than the other treatment groups, however only two patients in the int-adverse group underwent transplant, making the finding difficult to interpret. A multivariate analysis was also performed (Supporting Information Table S3 ) to detect whether survival with a particular treatment could be accounted for by using that treatment in int-favorable vs. int-adverse patients. No significant effect was noted outside of treatment with transplant in int-adverse patients, a finding again confounded by the very limited number of patients undergoing transplant. In summary, the treatment analysis most strongly suggested that the use of HMA therapy in int-favorable patients was beneficial.
| Validation of sequential stratification
First, an internal validation was performed using bootstrapping method.
Differences in median and 1-5-year survival rates between the two risk groups of patients (score 0-1 vs. score 2-4) are shown in Supporting Information Table S4 . The lower confidence limits of the 95% confidence intervals of the differences between the two risk groups were all greater than zero, indicating that there were statistically significant differences with respect to median and survival rates between the two groups (score 0-1 vs. score 2-4). The stratification was robust in the classification of patients with IPSS-R intermediate-risk myelodysplastic syndrome by internal validation.
Next we analyzed two additional independent datasets that included 111 and 616 IPSS-R int-risk MDS patients from two other, separate institutions, annotated for age, history of RBC transfusion, and presence of peripheral blood blast >2% at presentation. Summary patient characteristics of the external validation cohorts are provided in Supporting Information Table S5 . Each patient was assigned a score based on supplied information (Supporting Information Figure S3 ), and determined to be int-favorable risk (score < 2)
or int-adverse risk (score ≥ 2). For the first dataset (n = 111), survival rates among int-favorable and int-adverse patients were signifi- Information Tables S7-S9 and Supporting Information Figure S4 ). All lower confidence limits were ≥0 for external cohort 2, demonstrating significant differences for median survival and survival rates among int-favorable and int-adverse patients. In total, independent validation cohort data strongly supported the idea that int-risk MDS patients have heterogeneous outcomes and could be reliably sequentially stratified based on common characteristics even when evaluated at different institutions.
| DISCUSSION
In this analysis, we demonstrate that the outcomes of patients with Therapeutic guidelines are divided according to "lower risk" and "higher risk" MDS as established by conventional risk categories. 8, 17 Treatment for the higher risk group aims to modify the natural disease course with therapy, while a main priority for low-risk MDS is correction of cytopenias if present. 4 Patients with int-risk MDS are not limited to lower risk disease treatment options, may have resistance to first-line treatment, 18 and may require treatments appropriate for higher risk patients. 19 Our analysis demonstrates that patients classi- The IPSS and IPSS-R are good tools for predicting survival outcome and their prognostic impact has been validated by many studies. [25] [26] [27] Both tools may be deficient in how to incorporate transfusion history and dependency. The current analysis noted a significant difference in median overall survival for patients who demonstrated some dependency on RBC transfusion, compared to those who were not dependent (28 vs. 54 months). Transfusion dependence has also been noted as an independent prognostic factor previously. 28, 29 Malcovati et al. noted that the development of secondary iron overload in transfusion-dependent patients also significantly affected their survival (P = .003). 29 Although in our study ferritin levels of ≥1222 ng/mL were associated with significantly worse survival outcomes, these were not incorporated into the final risk model due to incompletely available data. Other studies have also detected the prognostic importance of ferritin, and whether that is a function of transfusion history or a surrogate marker (eg, for inflammation), is not well understood. [29] [30] [31] Serum β-2 microglobulin is also a relevant biomarker in predicting survival in MDS as well as risk of AML transformation. 30 In our dataset, baseline plasma β-2 microglobulin was not available for every patient and was not considered in the final model. Finally, the influence of prior erythropoietinstimulating agents and baseline erythropoietin levels was not evaluated, since this data was not captured.
Although both karyotype complexity and TET2 mutations have been implicated in accelerating leukemic transformation, no significant impact of mutated TET2 on survival has been reported. 32 Complex cytogenetics, on the other hand, have been associated with poor prognosis. 8, 17, 33 Mutation status and cytogenetics were not significant influential factors in the current study; however, cytogenetics were preselected for int-risk and mutational data was limited, highlighting a shortcoming of this analysis. The prognostic impact of a variety of MDS-associated mutations continues to undergo analysis as more patients have such testing, and its current use may not be available to all clinicians.
The sequential stratification based on patients from a single institution was further validated using bootstrap method, and with external data from two separate, independent institutions. 
